Alcidion Group (ALC) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Jun, 2026Executive summary
Selected as preferred supplier for North Cumbria Integrated Care NHS Foundation Trust's Electronic Patient Record (EPR) system, with an anticipated 10-year contract valued at AUD 30–40 million, pending finalization.
Signed a new 5-year partnership with Hume Rural Health Alliance in Victoria, covering 15 hospitals and focusing on patient flow and virtual care, valued at AUD 4 million.
Achieved record quarterly cash receipts of AUD 18.6 million in Q4 FY24, up from AUD 17.6 million in the prior period.
Positive operating cash flow of AUD 5.6 million in Q4 and AUD 4.3 million for H2 FY24, reversing earlier outflows.
Went live with new deployments at Hampshire Hospitals (Emergency Department module), Bolton NHS Foundation Trust (Flow), and Dartford (Medications Management and Miya e-Noting).
Financial highlights
FY24 unaudited revenue expected between AUD 37–37.5 million, with 74% recurring product revenue.
Q4 contract sales totaled AUD 5 million, with AUD 900,000 recognized in FY24; included a AUD 1.7 million renewal with NSW eHealth.
Cash balance at 30 June 2024 was AUD 11.8 million, with no debt.
Annualized cost savings of AUD 6.4 million achieved, with Q4 staff costs reduced to AUD 6.3 million from AUD 8.1 million in Q3.
FY24 operating cash outflow of AUD 7.1 million, impacted by a Q1 outflow of AUD 8.1 million.
Outlook and guidance
Approximately AUD 130 million in contracted and renewal revenue to be recognized over the next five years, excluding upside from expansions and the proposed North Cumbria contract.
Several opportunities progressing into procurement selection stages, with optimism for future contract wins.
Ongoing tender activity in ANZ and UK, with further updates expected at full year results.
Committed to profitability, with further details to be provided at full-year results.
Latest events from Alcidion Group
- Revenue down 8%, recurring revenue 74%, cost cuts drive improved H2 EBITDA and cash flow.ALC
H2 202429 May 2026 - Record new contracts and improved EBITDA drive strong FY25 outlook and profitability.ALC
H1 202529 May 2026 - Record revenue, 31% ARR growth, and major UK contracts drive strong FY26 outlook.ALC
H2 202529 May 2026 - H1 FY26 revenue up 44% and EBITDA up 675%, driven by major contract wins and expansions.ALC
H1 202629 May 2026 - Q3 FY2026 saw strong cashflow, record receipts, and robust contract growth, supporting FY2026 guidance.ALC
Q3 202629 Apr 2026 - Recurring revenue growth, cost savings, and new contracts support FY2025 profitability outlook.ALC
AGM 202419 Jan 2026 - Q1 FY25 saw $5.2M new sales, strong recurring revenue, and improved cash flow.ALC
Q1 202517 Jan 2026 - Q2 FY26 saw strong sales, 40% revenue growth, and a robust cash position with no debt.ALC
Q2 202615 Jan 2026 - Strong Q2 with major new contracts, robust recurring revenue, and positive full-year outlook.ALC
Q2 20259 Jan 2026